Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFTR | P13569 | 1/20 | 0.51 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.46 |
| ▸ | ESRRG | P62508 | 1/20 | 0.44 |
| ▸ | KIF11 | P52732 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 2/20 | 0.43 |
| ▸ | CA2 | P00918 | 2/20 | 0.43 |
| ▸ | CA9 | Q16790 | 2/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA7 | P43166 | 1/20 | 0.43 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.43 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.43 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17996053 | 0.87 | CFTR (0.47) | CFTREPHX2NR1H4ESRRGKIF11 | |
| SCHEMBL694388 | 0.86 | CFTR (0.69) | CFTRCA12CA2CA9CA1 | |
| SCHEMBL12203032 | 0.86 | CFTR (0.47) | CFTREPHX2NR1H4KIF11CA12 | |
| SCHEMBL23645185 | 0.84 | CFTR (0.51) | CFTRKIF11CA12CA2CA9 | |
| SCHEMBL25374714 | 0.83 | CFTR (0.53) | CFTRCA12CA2CA9CA1 | |
| SCHEMBL18512401 | 0.82 | CFTR (0.50) | CFTRNR1H4ESRRGKIF11CA12 | |
| SCHEMBL3157053 | 0.81 | CA12 (0.62) | CFTRNR1H4KIF11CA12CA2 | |
| SCHEMBL13945805 | 0.81 | CFTR (0.49) | CFTRNR1H4KIF11CA12CA2 | |
| SCHEMBL495841 | 0.80 | NR1H4 (0.60) | EPHX2NR1H4ESRRGKDM4EALDH1A1 | |
| SCHEMBL26804966 | 0.80 | NR1H4 (0.46) | EPHX2NR1H4ESRRGALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210070748-A1 | INHIBITORS OF BRUTONS TYROSINE KINASE | PHARMACYCLICS LLC (US) | 2021-03-11 | — | — | US | disclosed |
| US-20210070748-A1 | INHIBITORS OF BRUTONS TYROSINE KINASE | PHARMACYCLICS LLC (US) | 2021-03-11 | — | — | US | disclosed |
| US-20200190089-A1 | SMALL MOLECULE INHIBITORS OF NEUTRAL SPHINGOMYELINASE 2 (NSMASE2) FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY AS CR V.V.I. (CZ) | 2020-06-18 | — | — | US | disclosed |
| US-20180305348-A1 | INHIBITORS OF BRUTONS TYROSINE KINASE | PHARMACYCLICS LLC | 2018-10-25 | — | — | US | disclosed |
| EP-3310776-A2 | INHIBITORS OF BRUTON'S TYROSINE KINASE | Pharmacyclics LLC (US) | 2018-04-25 | — | — | EP | disclosed |
| WO-2016196776-A2 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS LLC. (US) | 2016-12-08 | — | — | WO | disclosed |
| WO-2016196776-A2 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS LLC. (US) | 2016-12-08 | — | — | WO | disclosed |
| EP-1955697-B1 | 2-AMINOBENZAMIDE DERIVATIVES AS VANILLOID RECEPTOR 1 (VR1) INHIBITORS USEFUL FOR THE TREATMENT OF PAIN OR BLADDER FUNCTION DISORDER | ASTELLAS PHARMA INC (JP) | 2012-05-02 | — | — | EP | disclosed |
| US-8106190-B2 | 2-aminobenzamide derivatives | ASTELLAS PHARMA INC. (JP) | 2012-01-31 | — | — | US | disclosed |
| US-20090233900-A1 | 2-AMINOBENZAMIDE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2009-09-17 | — | — | US | disclosed |
| EP-1955697-A1 | 2-AMINOBENZAMIDE DERIVATIVE | Astellas Pharma Inc. (JP) | 2008-08-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210070748-A1 | INHIBITORS OF BRUTONS TYROSINE KINASE | BTK, LYN, LCK | CFTR 1809/4885EPHX2 2317/4885NR1H4 4173/4885 |
| US-20090233900-A1 | 2-AMINOBENZAMIDE DERIVATIVE | TRPV1, TRPV2, TRPV5 | CFTR 2040/4885EPHX2 2325/4885NR1H4 2025/4885 |
| US-20200190089-A1 | SMALL MOLECULE INHIBITORS OF NEUTRAL SPHINGOMYELINASE 2 (NSMASE2) FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SMPD2, SPTLC2, SGMS2 | CFTR 4833/4885EPHX2 1680/4885NR1H4 4489/4885 |
| US-20180305348-A1 | INHIBITORS OF BRUTONS TYROSINE KINASE | BTK, LYN, LCK | CFTR 1809/4885EPHX2 2317/4885NR1H4 4173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.